Drug Trial Radar · NCT05695417
Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI in Subjects With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy
Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
22
Actual
Start
Jan 15, 2023
Primary completion
May 28, 2024
Study completion Jul 12, 2024
Sponsor
- Lead sponsor
- Ocular Therapeutix, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 25, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI in Subjects with Moderately Severe to Severe Non-proliferative Diabetic Retinopathy
Conditions
- Non-proliferative Diabetic Retinopathy
Interventions
OTX-TKIDrug
0.6 mg OTX-TKI intravitreal injection
ShamDrug
Sham
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and TolerabilityTime frame: Baseline up to Week 52
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
Ocular Therapeutix Inc
Phoenix, Arizona
Ocular Therapeutix, Inc.
Bakersfield, California
Ocular Therapeutix, Inc.
Augusta, Georgia
Ocular Therapeutix, Inc.
Lemont, Illinois
Ocular Therapeutix, Inc.
Hagerstown, Maryland
Ocular Therapeutix, Inc.
Reno, Nevada
Ocular Therapeutiux, Inc.
Austin, Texas
Ocular Therapeutix Inc
Bellaire, Texas
Ocular Therapeutix, Inc
San Antonio, Texas
Ocular Therapeutix Inc.
The Woodlands, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.